BSE: 531398
SOURCE NATURAL FOODS & HERBAL
Manufactures and sells herbal and ayurvedic supplements as its single reportable segment, with a growing diversification into renewable energy, EV charging, and waste management. The Ayurveda/herbal supplements business generated ₹55.5322 crore in FY26, supplemented by a new Energy vertical that contributed ₹21.7918 crore covering solar PV projects, EV charging stations, and wastewater and solid waste management. The company has set up two wholly owned subsidiaries — Source Natural Solar Private Limited and Source Natural Estates Private Limited — to house its renewable energy and waste management businesses. Material costs are the largest expense at 11.4% of revenue, followed by other operating expenses at 6.8% and employee costs at 6.4%, with EBITDA margin at 8.45% in FY26. Capital expenditure was 0.9% of revenue in FY26. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Ayurveda (herbal and ayurvedic supplements) (100%), Energy. Diversifying from a single-segment herbal supplements business into renewable energy, EV charging, and waste management through new subsidiaries.
Exhibit 1: Financial summary, – (all audited; no estimate years)
| ₹ crore · consolidated |
|---|
| Revenue |
| EBITDA (ex other income) |
| margin % |
| Owners' profit |
| EPS, as reported (₹) |
| ROE % · ROCE % |
| Debt / equity (x) |
| Cash from operations |
| Capex |
Exhibit 2: Quarterly performance, last 1 quarters
| ₹ crore | Q1 FY27 |
|---|---|
| Revenue | 21 |
| Profit before tax | 1 |
| Net profit | 1 |
| EPS (₹) | 1.06 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,20,165 | 34.8 | 5.01 | 22.5 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,51,896 | 86.3 | 15.03 | 65.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,538 | 73.9 | 8.90 | 38.9 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,17,055 | 26.1 | 3.96 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,15,722 | 105.7 | 21.31 | 64.4 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 1,09,385 | 33.9 | 2.86 | 14.6 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,09,060 | 32.3 | 3.16 | 16.7 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,03,353 | 50.6 | 6.24 | 28.4 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 103.8 | 30.1 | 142 of 158 | 10% |
| EBITDA margin | 6.1 | 17.5 | 138 of 165 | 17% |
| Market cap | 71 | 810 | 142 of 181 | 22% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 14 Oct 2026 · Reg 74(5) certificate filed, no demat/remat activity in Q2 FY27 | compliance | minimal | — | — |
| 1 Oct 2026 · New statutory auditor K.B. Nambiar appointed for five year term at AGM | management changes | medium | — | — |
| 1 Oct 2026 · Scrutinizer report on 31st AGM e-voting, all 6 resolutions passed | compliance | minimal | — | — |
| 30 Sept 2026 · Trading window closed for Q2 and H1 FY27 results | compliance | minimal | — | — |
| 30 Sept 2026 · 31st AGM proceedings on Sep 30, 2026 - all 6 resolutions passed | board shareholder meetings | low | — | — |
| 23 Sept 2026 · Source Natural Foods receives Ayush Quality Mark Certification | business updates | medium | — | — |
| 10 Sept 2026 · Newspaper notice filed for 31st AGM on 30 September 2026 | compliance | minimal | — | — |
| 8 Sept 2026 · Book Closure for 31st AGM from Sep 24 to Sep 30, 2026 | board shareholder meetings | low | — | — |
| 8 Sept 2026 · Notice of 31st AGM and Annual Report for FY 2025-26 | board shareholder meetings | low | — | — |
| 8 Sept 2026 · 31st AGM notice and annual report for FY2025-26 filed | board shareholder meetings | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.